Rapport Therapeutics
RAPP
NASDAQ
IPO2024
about RAPP
Rapport Therapeutics is a biopharmaceutical company focused on developing innovative RNA-based therapies to treat rare genetic diseases by targeting the underlying genetic mutations.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $31.92 | $33.00 | $30.47 | $524.11M | 223.84K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.75 | n/a | n/a | 0% | 0% | 0% |